Every 10-Q that TOTALIGENT INC (TGNT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TGNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TGNT filings page.
Totaligent, Inc. (TGNT) reported another pre-revenue quarter for the three and six months ended June 30, 2026, with no revenue and a six‑month net loss of $121,864, improved from $220,250 a year earlier. Operating expenses fell to $145,384 from $182,528, while other income benefited from a $57,591 gain on the change in fair value of derivative liabilities.
The balance sheet remains highly stressed. Total assets were only $208,853, including $665 of cash, against $2,200,456 of liabilities, driven by $811,335 of convertible notes in default, $93,486 of new notes payable and large accrued compensation to related parties. The company reported negative working capital of $2,198,515, an accumulated deficit of $2,682,495 and a stockholders’ deficit of $1,991,603, and explicitly states substantial doubt about its ability to continue as a going concern.
Capital structure is highly dilutive: common shares outstanding rose to 382,091,775 from 213,601,313, largely from conversion of 148,812 Series D preferred shares and convertible debt, with 527,211,073 additional common‑stock equivalents outstanding. Subsequent approval to increase authorized common shares from 500,000,000 to 5,000,000,000 expands future issuance capacity. A strategic agreement to acquire Aetherium Medical assets remains uncertain because required funding has not been raised.
Totaligent, Inc. reported another quarter with no revenue and a net loss of $108,090 for the three months ended March 31, 2026, an improvement from a $165,478 loss a year earlier mainly due to a gain on its derivative liability.
The balance sheet remains highly stressed: cash was only $467, current liabilities totaled $2,422,663, and stockholders’ deficit was $2,217,888, including $911,335 of convertible notes payable in default and a derivative liability of $250,107. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional debt or equity financing.
Totaligent continues to invest in its capitalized software, now $169,764, and is repositioning its person-based digital marketing platform toward deeper artificial intelligence integration, potential AI-focused acquisitions, and possible re-entry into privacy-focused cryptocurrency mining, while expecting to resume revenue-generating activities once development and strategic initiatives progress.
Totaligent, Inc. reported sharply weaker results for the nine months ended September 30, 2025 as it continues to build its person-based digital marketing platform. Revenue fell to $2,248 from $444,529 a year earlier, reflecting a major drop in managed campaign activity while the company focused on completing its BETA platform, which launched March 5, 2025. Net loss narrowed to $490,889 from $834,715, but the balance sheet remains highly constrained, with total assets of $285,955, current liabilities of $2,302,438 and a stockholders’ deficit of $2,016,483.
Cash declined to just $504, and management disclosed negative working capital of $2,204,434, raising substantial doubt about the company’s ability to continue as a going concern without new financing. During the period, Totaligent raised $230,000 through convertible notes payable, which now total $911,335 and are associated with a $221,589 derivative liability. A subsequent $100,000 note issued April 1, 2025 went into default on October 1, 2025. As of November 14, 2025, the company had 211,101,313 common shares outstanding and common stock held by non‑affiliates was valued at approximately $3.7 million.